Early studies suggested that Her2 overexpression in ovarian cancer was a frequent event; however, most recent studies using techniques validated in breast cancer suggest that Her2 overexpression and amplification frequency in ovarian cancer is, in fact, a much rarer event (Farley et al, 2009). Here, ERBB2 is linked to ovarian carcinoma.